Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Recruiting 7Unknown 4Terminated 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4Thoracic 2Head & Neck 2Gastrointestinal 2Sarcoma 1Other solid neoplasm 1Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Triple Negative Breast Neoplasms 2Breast Neoplasms 2Neoplasm Metastasis 1

Interventions

Cyclophosphamide 89Capecitabine 88Trastuzumab 81Docetaxel 81Paclitaxel 65Epirubicin 57pyrotinib 55Tamoxifen 54Letrozole 53Fulvestrant 49Vinorelbine 43Carboplatin 43Doxorubicin 41Radiotherapy 33Anastrozole 32exemestane 31Neoadjuvant Therapy 29palbociclib 27Drug Therapy 27Fluorouracil 24Bevacizumab 24pertuzumab 23Cisplatin 23eribulin 22Exercise 21130-nm albumin-bound paclitaxel 21Goserelin 20Gemcitabine 20Chemotherapy, Adjuvant 19Albumin-Bound Paclitaxel 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Unknown × famitinib × Breast × Clear all
NCT04395989 2023-12-22

FUTURE-SUPER

Fudan University

Phase 2 Unknown
139 enrolled
Breast

Triple Negative Breast Neoplasms

NCT04733417 2023-04-13

A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
35 enrolled
Breast

Breast Neoplasms

NCT04355858 2022-07-26

MULAN

Fudan University

Phase 2 Unknown
319 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT04129996 2022-01-11

A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)

Fudan University

Phase 2 Unknown
46 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡